Qinlock

Chemical Nameripretinib
Dosage FormTablets (oral; 50 mg)
Drug ClassKinase inhibitors
SystemDigestive
CompanyDeciphera Pharmaceuticals
Approval Year2020

Indication

  • Indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Qinlock (ripretinib) Prescribing Information.2020Deciphera Pharmaceuticals, LLC, Waltham, MA